High materiality9/10
Xeris Biopharma price target raised to $16 from $12 at Leerink
Why it may matterVerify against the original reporting
Strong Buy
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Leerink Partners raises XERS target to $16 from $12; current price ~$7.71, signaling strong upside potential.
- Leerink raises target to $16; price $7.71; ~108% upside.
Key facts
- 01
Target: $16
- 02
Posted price: $7.71
- 03
Analyst firm: Leerink Partners
- 04
Analyst: Roanna Ruiz
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.